Search

everythinglearnresearchcommunity

for

Search:↓

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

CDK4/6 inhibitors may cause hair loss in breast cancer patients.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Alpha-tocopherol does not prevent hair loss from doxorubicin.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

The rash resolved after stopping ponatinib.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

Etoposide makes radiation therapy more effective against tumors without major side effects.

Ki-67 levels do not predict treatment response in triple-negative breast cancer.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Rituximab may cause skin issues, but baricitinib can help improve them.

Hair loss can occur as a side effect of certain breast cancer treatments, but minoxidil can help regrow hair.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

A heart transplant patient developed a skin condition called epidermodysplasia verruciformis after taking immune-suppressing drugs.

LGD1069 effectively prevents breast tumors in mice without toxicity.

Targeting EGFR may help reduce hair loss from chemotherapy.